JPRN-jRCTs031220617招募中4 期
Single versus dual antiplatelet therapy for feMOrOpopliTeal lesion treated witH paclItaxEl-eluting device. - SMOOTHIE
Soga Yoshimitsu0 个研究点目标入组 400 人开始时间: 2023年2月8日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Patients with symptomatic superficial femoral artery(SFA)or proximal popliteal artery(PA)target lesions requiring peripheral revascularization(whether new or restenotic)
- •2. Patients scheduled for endovascular treatment(EVT)using a paclitaxel-eluting device(drug-eluting stent (DES)or drug-coated balloon(DCB))for the lesions of(1)above
- •3.Patients with a Rutherford classification of 2-4
- •4.Patients who can continue DAPT for 3 months
排除标准
- •1.Patients enrolled in other intervention trials
- •2.Patients with known hypersensitivity to paclitaxel
- •3.Patients contraindicated by the use of aspirin,thienopyridine drugs
- •4.Diseases including hemorrhagic diathesis
- •(other than thrombocytopenia,von Willebrand disease,hemophilia,etc.)
研究者
相似试验
招募中
3 期
To Compare Longterm Single versus Dual Antiplatelet Therapy In Ischemic Stroke due to atherosclerotic narrowing of blood vessel in the brain.CTRI/2022/01/039445Dr Rohit Bhatia
进行中（未招募）
1 期
Single versus Dual Antiplatelet Therapy in patients with Incomplete Revascularization after Coronary artery bypass graft surgeryEUCTR2017-001754-33-ITIVERSITÀ CAMPUS BIO-MEDICO DI ROMA800
已完成
不适用
oborI dual antiplatelet therapy as aPPropriate duratiON (NIPPON)Coronary Artery DiseaseJPRN-UMIN000006698PO Associations for Establishment of Evidence in Interventions4,598
尚未招募
不适用
Effect of potent P2Y12 inhibitor monotherapy after double antiplatelet therapy for 1 month after PCI in ACS patientsDiseases of the circulatory systemKCT0006861Chonnam National University Hospital2,000
进行中（未招募）
1 期
Assessment of Dual antiplatelet therapy versus Rivaroxaban In atrial Fibrillation patients Treated with left atrial appendage closure: The randomized ADRIFT Study - ADRIFTMedDRA version: 19.1 Level: PT Classification code 10003658 Term: Atrial fibrillation System Organ Class: 10007541 - Cardiac disordersEUCTR2017-001567-20-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)90